STAAR Surgical (NASDAQ:STAA - Get Free Report) is expected to post its Q2 2026 results after the market closes on Wednesday, August 12th. Analysts expect the company to announce earnings of $0.2214 per share and revenue of $90.5970 million for the quarter. Parties are encouraged to explore the company's upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 5:30 PM ET.
STAAR Surgical (NASDAQ:STAA - Get Free Report) last announced its earnings results on Wednesday, August 12th. The medical instruments supplier reported $0.39 EPS for the quarter, beating the consensus estimate of $0.22 by $0.17. STAAR Surgical had a return on equity of 9.05% and a net margin of 1.13%.The business had revenue of $93.54 million for the quarter, compared to analysts' expectations of $90.60 million. During the same period in the prior year, the business posted ($0.34) earnings per share. The firm's revenue was up 111.1% on a year-over-year basis. On average, analysts expect STAAR Surgical to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
STAAR Surgical Stock Performance
STAAR Surgical stock traded up $0.52 during mid-day trading on Tuesday, reaching $24.61. The stock had a trading volume of 358,005 shares, compared to its average volume of 1,188,651. STAAR Surgical has a fifty-two week low of $15.59 and a fifty-two week high of $35.87. The firm has a market capitalization of $1.23 billion, a PE ratio of 351.62 and a beta of 1.26. The stock's 50-day simple moving average is $26.69 and its 200-day simple moving average is $24.21.
Institutional Inflows and Outflows
Large investors have recently made changes to their positions in the business. Invesco Ltd. boosted its stake in STAAR Surgical by 0.6% during the 3rd quarter. Invesco Ltd. now owns 150,896 shares of the medical instruments supplier's stock worth $4,055,000 after purchasing an additional 956 shares during the last quarter. Caitong International Asset Management Co. Ltd grew its stake in shares of STAAR Surgical by 2,605.1% in the third quarter. Caitong International Asset Management Co. Ltd now owns 1,055 shares of the medical instruments supplier's stock worth $28,000 after acquiring an additional 1,016 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of STAAR Surgical by 2.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 52,535 shares of the medical instruments supplier's stock valued at $1,214,000 after buying an additional 1,234 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of STAAR Surgical by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,390 shares of the medical instruments supplier's stock valued at $518,000 after purchasing an additional 1,267 shares during the last quarter. Finally, Deutsche Bank AG increased its holdings in shares of STAAR Surgical by 3.7% in the 4th quarter. Deutsche Bank AG now owns 38,586 shares of the medical instruments supplier's stock valued at $891,000 after acquiring an additional 1,382 shares during the last quarter. 96.70% of the stock is owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
A number of research firms have issued reports on STAA. William Blair set a $33.00 price objective on shares of STAAR Surgical in a research report on Thursday. Zacks Research upgraded shares of STAAR Surgical from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, August 4th. Canaccord Genuity Group boosted their price target on STAAR Surgical from $27.00 to $32.00 and gave the company a "buy" rating in a research note on Thursday, May 14th. Stifel Nicolaus reduced their target price on shares of STAAR Surgical from $31.00 to $28.00 and set a "hold" rating for the company in a report on Monday. Finally, UBS Group set a $28.00 target price on shares of STAAR Surgical in a report on Monday. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, seven have given a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $28.40.
Read Our Latest Research Report on STAA
STAAR Surgical Company Profile
(
Get Free Report)
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists.
Featured Articles
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider STAAR Surgical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and STAAR Surgical wasn't on the list.
While STAAR Surgical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
